medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-21-8-15medsovet-2809Research ArticleКАРДИОЛОГИЯCARDIOLOGYВозможности применения апиксабана на разных этапах ведения больных с тромбоэмболией легочной артерииTherapeutic potential of apixaban at different stages of management of patients with pulmonary thromboembolismАверковО. В.AverkovO. V.

Аверков Олег Валерьевич – доктор медицинских наук, профессор кафедры госпитальной терапии лечебного факультета, Федеральное государственное бюджетное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской Федерации; заместитель главного врача, руководитель регионального сосудистого центра Государственного бюджетного учреждения здравоохранения города Москвы «Городская клиническая больница №15 им. О.М. Филатова Департамента здравоохранения города Москвы»

111539, г. Москва, ул. Вешняковская, 23, 

127994, ГСП-4, г. Москва, Рахмановский пер, д. 3

Averkov Oleg Valeryevich – Dr. of Sci. (Med.), Professor, Department of Hospital Therapy of the Medical Faculty, Federal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University», Ministry of Health of the Russian Federation; Deputy Chief Doctor, Head of the Regional Vascular Center of the State Budgetary Healthcare Institution of the Moscow city “Filatov City Clinical Hospital No. 15 of the Moscow Department of Health”

23 Veshnyakovskay Str., 111539, Moscow, 

3 Rakhmanovsky Per., Moscow, 127994, GSP-4

 

oleg.averkov@gmail.comВечоркоВ. И.VechorkoV. I.

Вечорко Валерий Иванович – кандидат медицинских наук, главный врач Государственного бюджетного учреждения здравоохранения города Москвы «Городская клиническая больница №15 им. О.М. Филатова Департамента здравоохранения города Москвы»; доцент кафедры госпитальной терапии лечебного факультета Федерального государственного бюджетного образовательного учреждения высшего образования «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской Федерации

111539, г. Москва, ул. Вешняковская, 23, 

127994, ГСП-4, г. Москва, Рахмановский пер, д. 3

 

Vechorko Valery Ivanovich – Cand. of Sci. (Med.), Chief Doctor of the State Budgetary Healthcare Institution of Moscow city «Filatov City Clinical Hospital No.15 of the Moscow Department of Health»; Associate Professor, Department of Hospital Therapy, Faculty of General Medicine, Federal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation

23 Veshnyakovskay Str., 111539, Moscow, 

3 Rakhmanovsky Per., Moscow, 127994, GSP-4

ШапсиговаО. А.ShapsigovaO. A.

Шапсигова Оксана Ауесовна – кандидат медицинских наук, заместитель главного врача по лечебной работе

111539, г. Москва, ул. Вешняковская, 23

Shapsigova Oksana Auesovna – Cand. of Sci. (Med.), Deputy Chief Doctor for Clinical Care, Head of the State Budgetary Healthcare Institution of Moscow city

23 Veshnyakovskay Str., 111539, Moscow

Государственное бюджетное учреждение здравоохранения города Москвы «Городская клиническая больница №15 им. О.М. Филатова Департамента здравоохранения города Москвы»; Федеральное государственное бюджетное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияFilatov City Clinical Hospital No.15 of the Moscow Department of Health; Pirogov Russian National Research Medical University of the Ministry of Health of RussiaRussian FederationГосударственное бюджетное учреждение здравоохранения города Москвы «Городская клиническая больница №15 им. О.М. Филатова Департамента здравоохранения города Москвы»РоссияFilatov City Clinical Hospital No.15 of the Moscow Department of HealthRussian Federation201817012019021815Copyright © Аверков О.В., Вечорко В.И., Шапсигова О.А., 20192019Аверков О.В., Вечорко В.И., Шапсигова О.А.Averkov O.V., Vechorko V.I., Shapsigova O.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2809

В статье обсуждаются проблемы антикоагулянтной терапии при тромбоэмболии легочной артерии. Четко обозначены основные преимущества и предпочтительное использование прямых селективных пероральных антикоагулянтов, представленных ингибитором тромбина дабигатраном и группой ингибиторов фактора Xa в составе апиксабана, эдоксабана и ривароксабана. Основное внимание уделено апиксабану, доказательная база которого позволяет рассматривать его как приоритетный антикоагулянт, использование которого уместно у большинства больных с тромбоэмболией легочной артерии с первых часов болезни и до многолетней вторичной профилактики.

The article discusses the issues of anticoagulant therapy in pulmonary thromboembolism. It clearly highlights the main advantages and the preferred use of direct selective oral anticoagulants represented by the thrombin inhibitor dabigatran and the factor Xa inhibitor group including apixaban, edoxaban and rivaroxaban. This article provides a thorough introduction of apixaban with an evidence base allowing to consider it a priority anticoagulant, which may be reasonably administered to the majority of patients with pulmonary thromboembolism from the first hours of the disease to many years of secondary prevention.

тромбоэмболия легочной артериилечениевторичная профилактикаантикоагулянтыапиксабанpulmonary embolismtreatmentsecondary preventionanticoagulantsapixabanReferencesCohen A.T., Agnelli G., Anderson F.A., et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98: 756-764.Cohen A.T., Agnelli G., Anderson F.A., et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98: 756-764.Klok F.A., Zondag W., van Kralingen K.W., et al. Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events. Am J Respir Crit Care Med. 2010; 181: 501–506.Klok F.A., Zondag W., van Kralingen K.W., et al. Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events. Am J Respir Crit Care Med. 2010; 181: 501–506.Tagalakis V., Patenaude V., Kahn S.R., Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013; 126(832): e13–e21.Tagalakis V., Patenaude V., Kahn S.R., Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013; 126(832): e13–e21.Strickers H. Chronic thromboembolic pulmonary hypertension – a diagnostic and therapeutic update. VASA. 2016; 45: 195–199.Strickers H. Chronic thromboembolic pulmonary hypertension – a diagnostic and therapeutic update. VASA. 2016; 45: 195–199.Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141: Suppl: e419S-e494S.Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141: Suppl: e419S-e494S.Ridker P.M., Goldhaber S.Z., Danielson E., Rosenberg Y., Eby C.S., Deitcher S.R., Cushman M., Moll S., Kessler C.M., Elliott C.G., Paulson R., Wong T., Bauer K.A., Schwartz B.A., Miletich J.P., Bounameaux H., Glynn R.J., for the PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 348: 1425-1434.Ridker P.M., Goldhaber S.Z., Danielson E., Rosenberg Y., Eby C.S., Deitcher S.R., Cushman M., Moll S., Kessler C.M., Elliott C.G., Paulson R., Wong T., Bauer K.A., Schwartz B.A., Miletich J.P., Bounameaux H., Glynn R.J., for the PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 348: 1425-1434.Kearon C., Ginsberg J.S., Kovacs M.J., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 349: 631-639.Kearon C., Ginsberg J.S., Kovacs M.J., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 349: 631-639.Buller H.R., Decousus H., Grosso M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406–1415.Buller H.R., Decousus H., Grosso M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406–1415.Schulman S., Kearon C., Kakkar A.K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med., 2009; 361: 2342-2352.Schulman S., Kearon C., Kakkar A.K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med., 2009; 361: 2342-2352.Schulman S., Kakkar A.K., Goldhaber S.Z., et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129: 764–772.Schulman S., Kakkar A.K., Goldhaber S.Z., et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129: 764–772.Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369: 799–808.Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369: 799–808.Bauersachs R., Berkowitz S.D., Brenner B., et al.. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;.363: 2499–2510.Bauersachs R., Berkowitz S.D., Brenner B., et al.. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;.363: 2499–2510.Buller H.R., Prins M.H., Lensin A.W. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366: 1287–1297.Buller H.R., Prins M.H., Lensin A.W. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366: 1287–1297.Prins M.H., Lensing A.W., Bauersachs R., et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013; 11: 21.Prins M.H., Lensing A.W., Bauersachs R., et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013; 11: 21.van der Hulle T., Kooiman J., den Exter P.L., Dekkers O.M., Klok F.A., Huisman M.V. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014; 12: 320–328.van der Hulle T., Kooiman J., den Exter P.L., Dekkers O.M., Klok F.A., Huisman M.V. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014; 12: 320–328.Raskob G.E., Gallus A.S., Sanders P., Thompson J.R., Agnelli G., Buller H.R., Cohen A.T., Ramacciotti E., Weitz J.I. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial Thromb Haemost. 2015 Dec 10; 115(4).Raskob G.E., Gallus A.S., Sanders P., Thompson J.R., Agnelli G., Buller H.R., Cohen A.T., Ramacciotti E., Weitz J.I. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial Thromb Haemost. 2015 Dec 10; 115(4).Schulman S., Kearon C., Kakkar A.K., et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013; 368: 709-718.Schulman S., Kearon C., Kakkar A.K., et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013; 368: 709-718.Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., Gallus A.S., Lensing A.W., Misselwitz F., Prins M.H., Raskob G.E., Segers A., Verhamme P., Wells P., Agnelli G., Bounameaux H., Cohen A., Davidson B.L., Piovella F., Schellong S. for the EINSTEIN investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med. 2010; 363(26): 2499-2510.Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., Gallus A.S., Lensing A.W., Misselwitz F., Prins M.H., Raskob G.E., Segers A., Verhamme P., Wells P., Agnelli G., Bounameaux H., Cohen A., Davidson B.L., Piovella F., Schellong S. for the EINSTEIN investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med. 2010; 363(26): 2499-2510.Agnelli G., Buller H.R., Cohen A., et al; AMPLIFYEXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699-708.Agnelli G., Buller H.R., Cohen A., et al; AMPLIFYEXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699-708.Weitz J.I., Lensing A.W., Prins M.H., et al; for the EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017. doi: 10.1056/NEJMoa1700518.Weitz J.I., Lensing A.W., Prins M.H., et al; for the EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017. doi: 10.1056/NEJMoa1700518.

The authors declare that there are no conflicts of interest present.